💸 USDT Users Catch Wind of Tether’s Sudden U-Turn: No More Freeze!

Initially, Tether, with what appeared to be the air of a stern schoolmaster, planned to put a full stop to its contracts on the first of September. But, as every Russian novelist knows, the power of the people-not developers and users, but the ones with the heart and the cry-is immense. The commotion that followed led to a more palatable course, letting Tether free to devote its resources to blockchains with the bustling lifeblood of proven adoption and sharp-witted developer activity.

Act I: The Cloud Comedy of Errors

Enter Mr. Stanley Druckenmiller, a man whose portfolio has weathered the tempests of time like a miser clutching his coins. In the second quarter, he laid claim to Microsoft (MSFT), a choice as prudent as it was theatrical. One might imagine him muttering, “What art thou, Azure, but a gilded server farm?” Yet lo! The company’s net profit of $102 billion on $282 billion in revenue suggests a certain alchemical prowess. The CFO, Amy Hood, declares their intent to “invest against the expansive opportunity,” a phrase so grandiose it might have been lifted from the lips of a baron boasting of his new château.

Cresco Labs: A Green Drama of Survival

Five years ago, a $1,000 bet on CRLBF would now fetch you a mere $200 and a sigh. Meanwhile, the S&P 500, that unassuming index, has grown the same sum to $1,878. A tale of two markets, perhaps? Or a parable of bureaucratic madness?

Crypto Billionaires: Genius or Madness? 🤪

Saylor, with his Strategy firm (a name that now feels tragically ironic 🧐), has embraced Bitcoin with the fervor of a religious convert. He doesn’t merely invest; he believes. He purchases in great gulps, financing these acquisitions by issuing more shares, a maneuver that would normally invite the scorn of any sensible investor. Yet, the market, in its fickle nature, has (until now) indulged him. It’s a curious game, this ‘infinite money glitch’ as they call it. A self-fulfilling prophecy built on…what, exactly? Hope? Hubris? Or simply a collective delusion?

Oklo: A Nuclear Energy Gamble Worth Considering?

But here’s the thing about underdogs: they don’t always stay on top. Oklo is still navigating what can only be described as a minefield of challenges. Does it have potential? Absolutely. Is it ready to justify its current valuation? Well, that’s where things get interesting-or complicated, depending on how you look at it.

3 Magnificent Stocks to Buy in September

To illuminate the path, three sages of Fool.com present their case for three stocks worthy of attention this September: Apple (AAPL), Airbnb (ABNB), and RH (RH). Let us examine their arguments with the detached curiosity such matters demand.

14 Sentenced to Life: Bitcoin Extortion & Kidnapping Saga 🎭💸 #CryptoChaos

Back in 2018, Shailesh Bhatt, a builder-cum-Bitcoin-trader, was snatched from a gas station by cops in official vehicles. *So* subtle, guys. 🙄 They whisked him off to a farmhouse, stole 200 Bitcoins (worth ₹12 crore then), and demanded ₹32 crore more. Bonus points for ambition! 🎯 Oh, and someone impersonated a CBI agent to lure him in. Truly a *dedicated* method actor. 🎭

Will Dogecoin’s Wild Ride 🐶💰 Spark the Next Crypto Frenzy? 🚀

Crypto analyst Unichartz, who I assume spends his weekends staring at candlesticks and muttering about Fibonacci retracements, has declared that Dogecoin is on the verge of a squeeze. And no, I don’t mean the kind of squeeze you do to a stress ball when your portfolio tanks. This is apparently a “promising structure,” whatever that means. According to him, DOGE is clinging to a rising support line like a cat on a windowsill during a thunderstorm. Buyers, it seems, are feeling bullish, which is either impressive or delusional given the broader crypto market’s current nosedive.

Dividend Dreams: ETF or DIY?

It’s an index-tracking ETF, which means its managers are basically just following a recipe. The recipe? The Dow Jones U.S. Dividend 100 index. Think of it as a dating app for stocks: only companies with a 10-year history of raising dividends get a profile. REITs? Out. It’s like a VIP lounge for financially stable, dividend-friendly corporations.

Dividend Dilemma: Realty Income or Pfizer?

Two titans of the dividend arena, Realty Income (O) and Pfizer (PFE), stand before us. Both have long histories of distributing dividends, though their paths diverge like those of two men at a crossroads-one with a map, the other with a compass.